*In adults (n=52) median age of earliest reported manifestations of HPP was 37.6 years (min: 0.2, max: 75.2), which preceded median age at diagnosis (47.5 years; min: 0.2, max: 75.2).¹ Data from the Global HPP Registry, sponsored by Alexion Pharmaceuticals, an observational, longitudinal, multinational, long-term study collecting data on HPP diagnosis, history, clinical course, symptoms (including multisystemic aspects of disease) and burden of illness from patients who have a diagnosis of HPP.¹^,³

*(N=160/213) Data from the Global HPP Registry, sponsored by Alexion Pharmaceuticals, an observational, longitudinal, multinational, long-term study collecting data on HPP diagnosis, history, clinical course, symptoms (including multisystemic aspects of disease) and burden of illness from patients who have a diagnosis of HPP.^1,6

*Skeletal manifestations were present in 44.2% (N=53/120) of paediatric (<18 years) and 48.2% (N=66/137) of adult (≥18 years) patients with HPP.¹ Data from the Global HPP Registry, sponsored by Alexion Pharmaceuticals, an observational, longitudinal, multinational, long-term study collecting data on HPP diagnosis, history, clinical course, symptoms (including multisystemic aspects of disease) and burden of illness from patients who have a diagnosis of HPPs.^{1,5 †}Includes craniosynostosis, developmental delay, increased intracranial pressure and seizures.^{1 ‡}Includes bone deformity, pseudofractures, recurrent and poorly healing fractures, rickets-like changes (by radiograph).¹

*Of 468 adults (skeletal group, n=300; muscular/pain group, n=73) from the Global HPP Registry, sponsored by Alexion Pharmaceuticals, an observational, longitudinal, multinational, long-term study collecting data on HPP diagnosis, history, clinical course, symptoms (including multisystemic aspects of disease) and burden of illness from patients who have a diagnosis of HPP.^{1,3 †}HAQ-DI disability assessment scores at baseline; N=191/239 (skeletal group) and N=47/239 (muscular/pain group).^{1  ‡}SF-36v2 domain scores at baseline. The individual SF-36v2 domain scores, except the physical functioning score, did not differ between the skeletal (N=191/238) and muscular/pain (N=47/238) groups.¹